ArticleScience advances2020
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.The Journal of clinical investigation · 2026Article
- Pre-existing activation states shape functional heterogeneity of human Vγ9Vδ2 T cells.Frontiers in immunology · 2026Article
- SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci.Nature biotechnology · 2025Article
- Current developments in T-cell receptor therapy for acute myeloid leukemia.Blood advances · 2025Review
- Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations.Journal of translational medicine · 2025Review
- CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.Science advances · 2025Article
- Ultra-high efficiency T cell reprogramming at multiple loci with SEED-Selection.bioRxiv : the preprint server for biology · 2024Article
- Challenges and solutions for therapeutic TCR-based agents.Immunological reviews · 2023Review
- The role of CD4MedComm · 2023Review
- Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy.Annual review of cancer biology · 2023Article
- Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control.Immunity · 2022Article
- A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.Cancer immunology research · 2022Article
- Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?Cancers · 2022Review
- Harnessing Antitumor CD4Cancers · 2022Review
- Single-cell transcriptomics of human gut T cells identifies cytotoxic CD4Frontiers in immunology · 2022Article
- Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia.Frontiers in immunology · 2022Article
- Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4Frontiers in immunology · 2022Article
- Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.Oncoimmunology · 2022Article
- Autoreactive T cell receptors with shared germline-like α chains in type 1 diabetes.JCI insight · 2021Article
- T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Jan A RathDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-8881-6060
Gagan BajwaCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.ORCID 0000-0001-8336-5635
Benoit CarreresDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-7532-7572
Elisabeth HoyerCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Isabelle GruberDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4871-9271
Melisa A Martínez-PaniaguaDepartment of Chemical and Biomolecular Engineering, University of Houston, TX, USA.ORCID 0000-0002-7275-4317
Yi-Ru YuDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3562-3502
Nazila NouraeeCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.ORCID 0000-0001-8560-1451
Fatemeh SadeghiDepartment of Chemical and Biomolecular Engineering, University of Houston, TX, USA.
Mengfen WuBiostatistics Shared Resource, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Tao WangBiostatistics Shared Resource, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Michael HebeisenDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Nathalie RuferDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
Navin VaradarajanDepartment of Chemical and Biomolecular Engineering, University of Houston, TX, USA.ORCID 0000-0001-7524-8228
Ping-Chih HoDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3078-3774
Malcolm K BrennerCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.ORCID 0000-0002-3657-7675
David GfellerDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3952-0930
Caroline ArberDepartment of Oncology UNIL-CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-6440-9970
Ludwig Cancer Research · CHHouston Methodist · USUniversity of Houston · USChildren's Cancer Center · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MQuantitative single-cell biomarkers of T-cells to optimize tumor immunotherapyR01CA174385 · NCI · UNIVERSITY OF HOUSTON · PI COOPER, LAURENCE J.N., VARADARAJAN, NAVIN · 2012 to 2015
$2.1MNCI NIH HHS P30 CA125123NCI NIH HHS R01 CA174385
Abstract
Transgenic coexpression of a class I-restricted tumor antigen-specific T cell receptor (TCR) and CD8αβ (TCR8) redirects antigen specificity of CD4
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAnimalsCD4-Positive T-LymphocytesCD8 AntigensHumansMiceReceptors, Antigen, T-CellTranscriptomeCD8alphabeta antigenCD8 AntigensReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.